Michigan lawmakers introduce bipartisan bill to curb China-U.S. biotech partnerships

A bipartisan group of Michigan legislators has unveiled a new bill aimed at limiting cross-border transactions between Chinese and American biotechnology firms.

The proposal, introduced by Rep. John Moolenaar and Rep. Debbie Dingell, argues that recent deals pose national-security risks and could undermine U.S. pharmaceutical innovation.

If enacted, the legislation would impose new review requirements and could significantly slow the rapid growth of China-U.S. biotech collaborations.